Sign up to save your podcasts
Or
Share Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Keeping Pace in Hematologic Malignancies: Novel Targets for Multiple Myeloma
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-novel-targets-for-multiple-myeloma/13824/
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 30-06-2023
Claim your CME credit at https://reachmd.com/programs/cme/keeping-pace-in-hematologic-malignancies-novel-targets-for-multiple-myeloma/13824/
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
=